What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?
December 23, 2025 |
Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.
Lucy McKay Megan Pullein
CEO Strategic Operations Officer
Medics for Rare Disease Medics for Rare Disease
Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?
Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.
Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.
Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?
Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.
Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?
Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.
Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.
Christy: Where does the work for each group start, and where does it end?
Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?
The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.
The final phase will be to consolidate this evidence into concrete recommendations.
Christy: What do you find most exciting about RDI-Lancet Commission?
Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.
It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.
Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.
For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract
About Medscape Education
Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
Elevating Nephrology Outcomes at #ERA23
Medscape is headed back to Milano, Italy for the 2023 European Renal Association conference, #ERA23.This year, the team is elevating the outcomes of recent nephrology education programs to share the story...
Medscape Education is Focusing on Patient Centricity and Education Outcomes at EHA 2023
The Medscape Education team will be on site at the 2023 EHA conference in Frankfurt, Germany to share the outcomes of recent hematology education programs and to advance the discussion on...
Shining a Spotlight on Women’s Health Education Outcomes at ACOG 2023
During the 2023 annual meeting of ACOG, Medscape highlighted the outcomes of CME/CE programs focused on improving clinicians knowledge and achieving better outcomes for patients. The outcomes were shared through...
Medscape Collaborates for Health Equity at DDW 2023
Recently, DDW 2023 took place in Chicago, IL, and Medscape was on-site with patient advocacy organizations to help educate clinicians on health equity in gastroenterology.Medscape was joined during the conference...
Real-World Impact of Continuing Medical Education on Physician Behavior in Prevention of Migraine
During the Alliance For Continuing Education in the Health Professions Industry Summit Medscape Education was awarded a Best in Class designation for its use of Real-World Outcomes to measure the impact of...
Medscape Present Outcomes of Neurology Education at AAN 2023
Medscape had education outcomes on the brain for this year’s AAN conference in Boston.During the conference, Medscape presented 5 scientific posters describing the impact of continuing medical education in migraine,...
Medscape Education Global Delivers Education and Outcomes to ECCMID 2023
Medscape Education Global has wrapped up its time in Copenhagen at ECCMID 2023. During the conference, Medscape Education Global had the opportunity to engage learners with an educational symposium and...
Antithrombotic Therapy for Peripheral Artery Disease: Medscape Education and Outcomes
At this year’s ACC2023 event, the Medscape Education team shared 7 posters highlighting the outcomes of cardiology continuing medical education (CME) programs. These posters covered a variety of cardiology topics...
Putting Skin in the Game at AAD 2023
AAD has wrapped up in New Orleans, and the Medscape team have returned home from another successful conference.During the conference, Medscape hosted one educational symposium, Reframing the Management Approach for...
Wrapping up EAU with a Look at Medscape’s Urology Impact
The Medscape Education Global team has returned from EAU in Milan, Italy, having presented an educational symposium and a networking event with Urology faculty and supporters.The educational symposium, Harnessing the...